top of page
Create a rectangular charcoal sketch of an emblematic waterfront Amsterdam canal bridge sk
TNS Logo

The partnering and investment summit for global leaders in CNS neuroscience drug discovery and development.

Feb - 25-27-2025

Amsterdam - The Netherlands

About

​Bio-Neuroscience convenes an outstanding mix of innovators, CEOs and decision-makers in CNS neuroscience drug development from the leading biotech companies, investors and pharma companies in the sector

Insight - Access - Engagement - Impact
Keynote speaker
Idea icon

Premier Gathering of Innovators

The one event which convenes a high-level, by-invitation, boutique gathering of thought leaders, innovators, CEOs and senior decision-makers from the leading stakeholders groups in CNS neuroscience drug development.

Expertise icon

The business of CNS Neuroscience drug development.

Where CEOs and C-level executives of the hottest companies come together with industry leaders, decision-makers, patient organizations, funders and the leading investors in CNS neuroscience drug development to dive into the the issues that matter most to stakeholders.

Investors icon

Elevating Engagement and Collaboration

A unique level of sustained high-quality discussion, access, engagement and partnering in a truly curated  summit unlike other events. 

Broadreach Summits - What Participants Say

“.png
A masterfully organized holistic view of developments in policy, clinical and business strategy, patient care and investment.

Pawel Swieboda

Director General

“.png
A masterfully organized holistic view of developments in policy, clinical and business strategy, patient care and investment.

Pawel Swieboda

Director General

image 10.png
Vision

Convening the full value chain to disrupt silos and curate highly interactive, multi-disciplinary, cross-industry, and multi-stakeholder discussions of opportunities, challenges, hurdles and ways forward.

Drive transformational connections, discussion and partnering for startups and growth companies.

 

Deliver insight, access, engagement and partnering to foster innovation and accelerate value creation.

 

Contribute to meaningful improvement in healthcare outcomes and positive impact for patients and society.

 

Get feedback and advice on your business, your objectives and your core challenges from leading innovators, investors and industry leaders in CNS neuroscience drug development.  

image 11.png
Why Now?

Now is the time for CNS neuroscience drug development. We have entered a time when truly rational drug discovery and development is possible and where new discoveries, tools, technologies, biomarkers and insights enable improved development.

Investor and industry interest is booming, yet key challenges remain that can only be addressed by bringing together the leading translational research, clinicians, entrepreneurs, CEOs, CSOs and CMOs from the leading biotech companies, with relevant therapeutic area and business development heads from big pharma and large biotech, as well as the Partners and Directors heading neuroscience investment at the most active and important investment funds.

 

The 2024 pilot edition established Bio-Neuroscience as a unique, high-level and interactive summit providing participants exceptional value in terms of the experience, insight, access and impact.

shutterstock_128316104 Thinking Impulses copy.jpg

Meet the Advisory Board

Advisory Board

Stacie Weninger

Executive Director - F-Prime Biomedical Research Initiative

Hakan Goker

Managing Director, Head of Healthcare & Life Sciences - M-Ventures

Joachim Scholpp

Global Head Translational Medicine CNS & Emerging Areas - Boehringer Ingelheim

Sourav Kole

Managing Director - Dolby Family Ventures

Rita Balice-Gordon

Chief Executive Officer - Muna Therapeutics

Martien Kas

President - European College of NeuroPsychopharmacology (ECNP)

Kalpana Merchant

CSO - Retromer Therapeutics, Adjunct Prof. Northwestern University Feinberg School of Medicine

Kees Been

Chief Executive Officer - Kynexis Therapeutics Inc.

Pieter van Bokhoven

Chief Scientific Officer - IXA Amsterdam Neuroscience UMC

Juan Carlos Lopez

Managing Director - Haystack Science, formerly Chief Editor - Nature Medicine & Founding Editor - Nature Reviews Neuroscience

Andrea Soto Padilla

Business Development - Amsterdam UMC

Mark Treherne

Chairperson - Monument Therapeutics, Commercial Scientists, Investor, Chair of Talisman Therapeutics, Ubiquent, NuVision Biotherapies

Advisory Board

Speakers - from the 2024 pilot - the 2025 lineup will be announced soon!

Proudly convening leading speakers and stakeholders from across the sector

Florian Brand

CEO & Co-Founder - atai Life Sciences

Raúl Ruíz-Martinez

Partner - Ysios Capital

José Luís Lanciego

Chair – International Brain Research Organization (IBRO) Pan European
Committee, Head – Laboratory of Functional Neuroanatomy of the Basal Ganglia, CNS Gene Therapy Program – CIMA, University of Navarra

Frédéric Destébecq

Executive Director - European Brain Council (EBC) & European Brain Foundation (EBF)

Anela Vukoja

COO - Apollo Health Ventures

Mary Chamberlain-Tharp

Chief Business Officer - Neumora

Cillian King

Managing Director - EQT Life Sciences

Aaron Koening

Chief Medical Officer - Delix Therapeutics

Jim Sullivan

CEO & Co-Founder - Vanqua Bio, Venture Partner - Orbimed

Delphine Charvin

Operating Partner - ARGOBIO Studio

Philip Scheltens

Head, Dementia Fund, Partner - EQT Life Sciences

Claire Leurent

Managing Director - AbbVie Ventures

Craig Thompson

CEO - Cerevance

Carlos Buesa

Founder & Chairman of the Board - Oryzon

Hilgo Bruining

Prof. Neurobiological Developmental Disorders - Amsterdam UMC, Chair N=You Neurodevelopmental Precision Center

Olga Krylova

Director, Business Development & Innovation - Otsuka

Jasper Bos

General Partner - Forbion

Yael Weiss

CEO - Mahzi Therapeutics

Terry Pirovolakis

Founder & CEO - Elpida Therapeutics

Christian Thomsen

Global Head, CNS BD&L - Boehringer Ingelheim

Niels Plath

Chief Scientific Officer - Muna Therapeutics

Maria Luis Pineda

CEO & Co-Founder - Envisagenics

John Kastelein

CEO - New Amsterdam Pharma, Operating Partner - Forbion

image 24.png

Presenting Companies

Benefit From
Tick icon

Pre-summit guidance and feedback on your deck.

​An on-site dry-run presentation with feedback and coaching from expert mentors.

5 minute presentation followed by 3 minutes Q&A with an expert panel of relevant investors and industry: In the plenary session.

Join a curated selection of the most innovative, promising and high potential companies with potential to transform CNS neuroscience drug development & treatment. Selection is by excellence and potential, not by price tag! There is no cost to present beyond the regular startup or private company registration fees.

Tick icon

Exclusive post presentation meeting space.

Prominently positioned in the main networking area to facilitate additional post presentation discussion in the 45 minute networking break immediately following your presentation session.

Tick icon

2 Days of sustained engagement with the best network of innovators, investors, industry leaders & decision-makers in CNS neuroscience drug development.

​Option to add an exclusive company exhibition stand.

Who's Coming

Two days of sustained, interactive discussion, networking and partnering with:

image 15.png
Industry Leaders

Industry decison-makers, Heads of Therapeutic Area,  Scouting, Alliance Management, Business Development & Licensing, Strategy & Portfolio from pharma & large biotech.

image 15 (1).png
Key Opinion Leaders

Key Opinion Leaders  from research, clinical development & care, strategy, finance, business development, licensing, regulatory, market launch & M&A. 

image 16.png
Founders & CEOs

Founders, CEOs & C-Level from the most innovative and hottest CNS neuroscience companies leading innovation & deals in the sector.

image 15 (2).png
Government & NGOs

Public funding bodies, policy makers, public agencies, societies, associations & NGOs in neuroscience, agencies, regulatory bodies.

image 17.png
Investors

Managing Partners & Partners from the most active CNS Neuroscience investing VC funds, Managing Directors & Directors of the leading Corporate Venture, Private Equity and Family Office Funds, Foundations & more.

image 15 (3).png
Patients 

A selected group of leading patient driven companies, non profits, foundations, associations and charities focused on the development of novel therapies for patients. 

Venue

Bio-Neuroscience brings together an outstanding mix of leaders and decision-makers in CNS Neuroscience drug development.

FC Exterior
Hotel Jakarta
Javakade 766, 1019 SH Amsterdam,
Netherlands

Bio-Neuroscience takes place at Hotel Jakarta, a sustainable modern hotel designed as a green oasis on the IJ river. The selection of the Hotel Jakarta Amsterdam as the new venue was made based on its central location, comfortable rooms and green atmosphere, and a setup which is well suited for the highly interactive but boutique interactive nature of Bio-Neuroscience, including improved plenary spaces, natural light, and increased networking space for business development and networking.

Meet Our
Sponsors & Partners

Co-Organizer and Host Partner

logo-Amsterdam-Neuroscience-2016-1920x36
Association Partners
EBC Logo
ECNP logo
BID logo
Strategic Partners 
Effectia Logo

Proud to support the European Brain Council's call to prioritize brain health.

Networking snap Bio-Neuro pilot.png

Get In Touch

Access - Insight - Engagement - Impact

Presenter icon

Nominate a speaker

Presenter icon

Apply to present your company or technology

Presenter icon

Enquire about sponsorship & exhibition opportunities

Thanks, message received. We'll be in touch shortly.

Contact Us
image 24 (1).png
Broadreach Global logo
Be the first to know
LinkedIn icon

broadreach-global

Copyright © 2023. All rights reserved. Broadreach Global LLC.

Terms Of Use & Privacy

bottom of page